Claims:

1. A compound represented by formula I or II:



(I) or



(II),

or a pharmaceutically acceptable salt thereof, wherein:

R^1 is hydrogen, halogen, amino, hydroxyl, alkoxy, or alkylthio;

W is N;

V and X are selected such that either V is CR^a and X is N, or V is N and X is CR^b;

R^a is hydrogen, halogen, hydroxyl, alkoxy, alkylthio, or alkyl;

R^b is hydrogen, halogen, hydroxyl, alkoxy, alkylthio, alkyl, alkenyl, alkynyl, aralkyl, heteroaralkyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl;

each U independently is N or CR^c;

each R^c independently is hydrogen, halogen, alkyl, or alkoxy;

ring Z^1 is aryl or a five-or six-membered heteroaryl;

ring Z^2 is a five- or six-membered heterocycle;

each R^2 independently is halogen, cyano, amino, acylamino, amido, hydroxyl, alkoxy, acyl, carbamoyl, carboxyl, carboxyester, guanidine, haloalkyl, haloalkoxy, $-O(CH_2CH_2O)_rR^4$, $-OCH_2C(O)N(R^4)_2$, heteroalkyl, imino, dialkylphosphine oxide, sulfonyl, sulfonamido, sulfonyl urea, alkyl, aralkyl, heteroaralkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl; or two vicinal R^2, together with the intervening carbon atom or carbon atoms to which they attach, combine to form a 5- or 6-membered carbocycle, 5- or 6-membered heterocycle, 5- or 6-membered aryl, or 5- or 6-membered heteroaryl; and

R^4 is alkyl, alkenyl, carbocyclyl, heterocyclyl, aryl or heteroaryl; or two R^4, together with the nitrogen atom, complete a 5- to 6-membered heterocycle; r is an integer selected from 1-6;

n is 0 or an integer selected from 1-4, as valency permits;

each R^6 independently is halogen, amino, acylamino, amido, hydroxyl, oxo, carboxyl, alkoxy, acyl, carbamoyl, carboxyl, carboxyester, guanidine, haloalkyl, haloalkoxy, heteroalkyl, imino, sulfonamido, sulfonyl urea, alkyl, alkenyl, alkynyl, aralkyl, heteroaralkyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl; or any two R^6, together with the intervening carbon atom(s) to which they attach, combine to form a carbocycle or heterocycle;

q is 0 or an integer selected from 1-4, as valency permits;

R^3 is  or  ;

M is $N(R^8)_3$, $N(R^8)_2$, OR^8 or SR^8;

each R^8 is independently hydrogen, alkyl, aralkyl, heteroaralkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl; and

R^{3a} and R^{3b} independently are hydrogen, alkyl, acyl, alkenyl, alkynyl, aralkyl, heteroaralkyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl; or R^{3a} and R^{3b}, together with the boron atom and the two intervening oxygen atoms that separate them, combine to form a monocyclic or polycyclic heterocyclyl; or R^{3a}, R^{3b}, and M, together with the boron atom and the intervening oxygen atoms, combine to form a polycyclic heterocycle.

2. The compound of claim 1, wherein the compound is represented by formula I-a or II-a:

 (I-a) or  (II-a);

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 or 2, wherein R^1 is hydroxyl or $C_{1\text{-}3}$ alkoxy, or wherein R^1 is amino and is preferably $-NH_2$ or $-NHCH_3$.

4. The compound of any one of claims 1 to 3, wherein each R^2 independently is halogen, cyano, amino, acylamino, amido, hydroxyl, alkoxy, haloalkoxy, dialkylphosphine oxide, alkyl, haloalkyl, aralkyl, heteroaralkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl;

or two vicinal R^2, together with the intervening carbon atoms to which they attach, combine to form a 5- or 6-membered carbocycle, 5- or 6-membered heterocycle, 5- or 6-membered aryl, or 5- or 6-membered heteroaryl, preferably wherein each R^2 independently is halogen, cyano, amino, acylamino, amido, hydroxyl, alkoxy, dialkylphosphine oxide, haloalkyl, sulfonyl, alkyl, carbocyclyl, heterocyclyl, aryl, aralkyl, heteroaralkyl or heteroaryl.

5. The compound of any one of claims 1 to 3, wherein:

each R^2 independently is -F, cyano, $-C(O)N(R^4)_2$, $-N(H)C(O)R^4$, $-OCF_3$, $-OCH_2C(O)N(R^4)_2$, $-O(CH_2CH_2O)_rR^4$, $-CF_3$, $-CHF_2$, $-OCH_3$, $-P(=O)(CH_3)_2$, $-CH_2COOH$, $-CH_3$, $-C_2H_5$, cyclopropyl, tetrahydropyranyl, 1,1-dioxo-1,2,5-thiadiazolidinyl or pyridinyl; or

wherein:

each R^2 independently is -F, cyano, $-N(H)C(O)R^4$, $-OCF_3$, $-OCH_2C(O)N(R^4)_2$, $-O(CH_2CH_2O)_rR^4$, $-CF_3$, $-CHF_2$, $-OCH_3$, $-P(=O)(CH_3)_2$, $-CH_3$, $-C_2H_5$, cyclopropyl, tetrahydropyranyl, 1,1-dioxo-1,2,5-thiadiazolidinyl or pyridinyl; and

R^4 is alkyl, alkenyl, carbocyclyl, heterocyclyl, aryl or heteroaryl, optionally wherein each R^2 is independently substituted with deuterium.

6. The compound of any one of claims 1-3, wherein two vicinal R^2, together with the intervening carbon atoms to which they attach, combine to form a 5- or 6-membered carbocycle, 5- or 6-membered heterocycle, 5- or 6-membered aryl ring, or 5- or 6-membered heteroaryl ring, preferably wherein two vicinal R^2, together with the intervening carbon atoms to which they attach, combine to form a 5- or 6-membered heteroaryl ring, optionally wherein the 5- or 6-membered heteroaryl ring is furan, pyrazole, thiazole, or oxazole, or wherein two vicinal R^2, together with the intervening carbon atoms to which they attach, combine to form a 5- or 6-membered heterocycle, optionally wherein the 5- or 6-membered heterocycle is dihydrofuran or dihydropyran.

7. The compound of any one of claims 1 to 6, wherein R^a is hydrogen, halogen, hydroxyl, alkoxy or alkyl, preferably wherein R^a is hydrogen.

8. The compound of any one of claims 1 to 7, wherein R^b is hydrogen, halogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, preferably wherein R^b is hydrogen, C_1-C_3 alkyl, or cyclopropyl, preferably methyl.

9. The compound of any one of claims 1 to 8, wherein each R^c independently is hydrogen, halogen, or alkyl.

10. The compound of any one of claims 1 to 9, wherein W and X are N and V is CR^a, optionally wherein R^a is hydrogen.

11. The compound of claim 10, wherein V and W are N and X is CR^b, preferably wherein R^b is methyl.

12. The compound of any one of claims 1 to 11, wherein U is CR^c, optionally wherein R^c is hydrogen, F, methyl, methoxy, or Cl.

13. The compound of any one of claims 1 to 12, wherein ring Z^1 is phenyl or a five- or six-membered heteroaryl.

14. The compound of claim 13, wherein the compound is represented by formula I-b or II-b:



(I-b) or



(II-b);

or a pharmaceutically acceptable salt thereof.

15. The compound of claim 13, wherein ring Z^1 is a five- or six-membered heteroaryl, optionally wherein ring Z^1 is a pyrazolyl or a pyridinyl.

16. The compound of claim 15, wherein the compound is a compound represented by formula I-c or II-c:



(I-c) or



(II-c);

or a pharmaceutically acceptable salt thereof.

17. A compound represented by formula I-c-1 or I-c-2:



(I-c-1) or



(I-c-2),

or a pharmaceutically acceptable salt thereof, wherein:

each R^2 independently is halogen, cyano, amino, acylamino, amido, hydroxyl, alkoxy, acyl, carbamoyl, carboxyl, carboxyester, guanidine, haloalkyl, haloalkoxy, $-O(CH_2CH_2O)_rR^4$, $-OCH_2C(O)N(R^4)_2$, heteroalkyl, imino, dialkylphosphine oxide, sulfonyl, sulfonamido, sulfonyl urea, alkyl, aralkyl, heteroaralkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl; or

two vicinal R^2, together with the intervening carbon atom or carbon atoms to which they attach, combine to form a 5- or 6-membered carbocycle, 5- or 6-membered heterocycle, 5- or 6-membered aryl, or 5- or 6-membered heteroaryl;

R^{2a} is alkyl, aralkyl, heteroaralkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl;

n is 0 or an integer selected from 1-4, as valency permits;

R^3 is  or  ;

M is $N(R^8)_3$, $N(R^8)_2$, OR^8 or SR^8;

each R^8 is independently hydrogen, alkyl, aralkyl, heteroaralkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl;

R^{3a} and R^{3b} independently are hydrogen, alkyl, acyl, alkenyl, alkynyl, aralkyl, heteroaralkyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl; or

R^{3a} and R^{3b}, together with the boron atom and the two intervening oxygen atoms that separate them, combine to form a monocyclic or polycyclic heterocyclyl; or

R^{3a}, R^{3b}, and M, together with the boron atom and the intervening oxygen atoms, combine to form a polycyclic heterocycle;

R^4 is alkyl, alkenyl, carbocyclyl, heterocyclyl, aryl or heteroaryl; or two R^4, together with the nitrogen atom, complete a 5- to 6-membered heterocycle; and

r is an integer selected from 1-6.

18. The compound of claim 17, wherein R^{2a} is methyl, difluoromethyl, $-CF_2CHF_2$, $-CHFCF_3$, $-CH_2CF_3$, $-(CH_2CH_2O)_2CH_3$,  ,  , 

 or  , wherein m is an integer from 2 to 6.

19. The compound of any one of claims 1 to 18, wherein R^3 is

 ,

optionally wherein R^{3a} and R^{3b} independently are hydrogen, alkyl, acyl, alkenyl, alkynyl, aralkyl, heteroaralkyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl, preferably wherein R^{3a} and R^{3b} are hydrogen or

wherein R^{3a} and R^{3b}, together with the boron atom and the two intervening oxygen atoms that separate them, combine such that R^3 is a heterocyclyl.

20. The compound of claim 19, wherein R^3 is

 ,

wherein:

each R^5 independently is halogen, nitro, cyano, amino, acylamino, amido, hydroxyl, oxo, carboxy, alkoxy, alkylthio, alkyl (e.g., carboxymethyl), aralkyl, heteroaralkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl; or any two R^5, independently, together with the intervening carbon atom(s) to which they attach, combine to form a carbocycle or heterocycle; and

p is 0 or an integer selected from 1-6, as valency permits, optionally wherein R^3 is



21. The compound of any one of claims 1 to 18, wherein

R^3 is



; and

R^{3a}, R^{3b}, and M, together with the boron atom and the intervening atoms, combine such that R^3 is a polycyclic heterocycle, optionally wherein R^3 is



, wherein R^d is H or C_1-C_4 alkyl, preferably wherein R^d is H or methyl.

22. The compound of any one of claims 1-13, wherein the compound is represented by formula II-b-1,II-b-2, or II-b-3:



(II-b-1),



(II-b-2),



or (II-b-3);

or a pharmaceutically acceptable salt thereof;

optionally wherein each R^6 independently is halogen, alkyl, carbocyclyl, allyl, or oxo, or optionally wherein each R^6 independently is halogen, alkyl, or oxo.

23. The compound of claim 22, wherein ring Z^2 is



24. The compound of claim 22 or 23, wherein R^{3a} is hydrogen or methyl.

25. A compound selected from:

 ,  ,  ,

 ,  ,  ,

 ,  ,  ,

 ,  ,  ,

 ,  ,  ,

 ,  ,  ,  ,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

, and

,

or a pharmaceutically acceptable salt thereof.

26. The compound according to claim 25, wherein the compound is:



or a pharmaceutically acceptable salt thereof.

27. The compound according to claim 25, wherein the compound is:



or a pharmaceutically acceptable salt thereof.

28. The compound according to claim 25, wherein the compound is:



or a pharmaceutically acceptable salt thereof.

29. The compound according to claim 25, wherein the compound is:



or a pharmaceutically acceptable salt thereof.

30. The compound according to claim 25, wherein the compound is:



or a pharmaceutically acceptable salt thereof.

31. The compound according to claim 25, wherein the compound is:



or a pharmaceutically acceptable salt thereof.

32. The compound according to claim 25, wherein the compound is:



or a pharmaceutically acceptable salt thereof.

33. The compound according to claim 25, wherein the compound is:



or a pharmaceutically acceptable salt thereof.

34. The compound according to claim 25, wherein the compound is:



or a pharmaceutically acceptable salt thereof.

35. The compound according to claim 25, wherein the compound is:



or a pharmaceutically acceptable salt thereof.

36. The compound according to claim 25, wherein the compound is:



or a pharmaceutically acceptable salt thereof.



37. The compound according to claim 25, wherein the compound is:

or a pharmaceutically acceptable salt thereof.

38. The compound according to claim 25, wherein the compound is:



or a pharmaceutically acceptable salt thereof.

39. The compound according to claim 25, wherein the compound is:



or a pharmaceutically acceptable salt thereof.

40. The compound according to claim 25, wherein the compound is:



or a pharmaceutically acceptable salt thereof.

41. The compound according to claim 25, wherein the compound is:



or a pharmaceutically acceptable salt thereof.

42. The compound according to claim 25, wherein the compound is:



or a pharmaceutically acceptable salt thereof.

43. The compound according to claim 25, wherein the compound is:



or a pharmaceutically acceptable salt thereof.

44. The compound according to claim 25, wherein the compound is:



or a pharmaceutically acceptable salt thereof.

45. The compound according to claim 25, wherein the compound is:



or a pharmaceutically acceptable salt thereof.

46. The compound according to claim 25, wherein the compound is:



or a pharmaceutically acceptable salt thereof.

47. A pharmaceutical composition, comprising the compound of any one of claims 1 to 46 and a pharmaceutically acceptable excipient.

48. A compound of any one of claims 1-46 for use in treating a disease or condition associated with complement activation selected from a neurodegenerative disorder, an inflammatory disease, an autoimmune disease, an ophthalmic disease, or a metabolic disorder.

49. The compound or use of claim 48, wherein the disease or condition associated with complement activation is chosen from Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, progressive multiple sclerosis, glaucoma, myotonic dystrophy, Guillain-Barre´ syndrome, Myasthenia Gravis, spinal muscular atrophy, Down syndrome, Parkinson's disease,

Huntington's disease, traumatic brain injury, epilepsy, frontotemporal dementia, diabetes, obesity, atherosclerosis, rheumatoid arthritis, acute respiratory distress syndrome, pemphigus, pemphigus vulgaris, pemphigus foliaceus, bullous pemphigoid, immune-mediated necrotizing myopathy, vitiligo, paraneoplastic syndromes, a vasculitis disease, hypocomplementemic urticarial vasculitis, chronic spontaneous urticaria, remote tissue injury after ischemia and reperfusion, complement activation during cardiopulmonary bypass surgery, dermatomyositis, lupus nephritis and resultant glomerulonephritis and vasculitis, kidney fibrosis, systemic lupus erythematosus, Hashimoto's thyroiditis, Addison's disease, Celiac disease, Crohn's disease, pernicious anemia, chronic idiopathic demyelinating polyneuropathy, multifocal motor neuropathy, heparin-induced thrombocytopenia, idiopathic thrombocytopenic purpura, cardioplegia-induced coronary endothelial dysfunction, type II membranoproliferative glomerulonephritis, IgA nephropathy, acute renal failure, cryoglobulemia, antiphospholipid syndrome, chronic open-angle glaucoma, acute closed angle glaucoma, macular degenerative diseases, wet age-related macular degeneration, dry age-related macular degeneration, geographic atrophy, choroidal neovascularization, uveitis, diabetic retinopathy, ischemia-related retinopathy, endophthalmitis, intraocular neovascular disease, diabetic macular edema, pathological myopia, von Hippel-Lindau disease, histoplasmosis of the eye, neuromyelitis optica, central retinal vein occlusion , corneal neovascularization, retinal neovascularization, Leber's hereditary optic neuropathy, optic neuritis, Behcet's retinopathy, ischemic optic neuropathy, retinal vasculitis, ANCA vasculitis, Wegener's granulomatosis, Purtscher retinopathy, Sjogren's dry eye disease, sarcoidosis, temporal arteritis, polyarteritis nodosa, allo-transplantation, hyperacute rejection, hemodialysis, chronic occlusive pulmonary distress syndrome, asthma, aspiration pneumonia, immune thrombocytopenia, autoimmune hemolytic anemia, cold agglutinin disease, warm autoimmune hemolytic anemia and coronary artery disease.